Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards
1. HOTH's HT-KIT shows rapid anti-tumor efficacy in preclinical models. 2. The candidate achieved over 80% knockdown of oncogenic KIT expression. 3. HT-KIT demonstrates a clean safety profile with no off-target toxicity. 4. GLP-validated results exceed regulatory thresholds, boosting HOTH's credibility. 5. Company aims for IND submission and first-in-human trials next.